The linkage of neurodegenerative diseases with insulin resistance (IR) and type 2 diabetes mellitus (T2DM), including oxidative stress, mitochondrial dysfunction, excessive inflammatory responses and abnormal protein processing, and the correlation between cerebrovascular diseases and hyperglycemia has opened a new window for novel therapeutics for these cognitive disorders. Various antidiabetic agents have been studied for their potential treatment of cognitive disorders, among which the dipeptidyl peptidase-4 (DPP-4) inhibitors have been investigated more recently. So far, DPP-4 inhibitors have demonstrated neuroprotection and cognitive improvements in animal models, and cognitive benefits in diabetic patients with or without cognitive impairments. This review aims to summarize the potential mechanisms, advantages and limitations, and currently available evidence for developing DPP-4 inhibitors as a treatment of cognitive disorders.

中文翻译：

---

二肽基肽酶-4抑制剂可以治疗认知障碍吗？

神经退行性疾病与胰岛素抵抗（IR）和2型糖尿病（T2DM）的联系，包括氧化应激，线粒体功能障碍，过度的炎症反应和异常的蛋白质加工，以及脑血管疾病和高血糖之间的相关性，为新的疾病打开了新的窗口这些认知障碍的疗法。已经研究了各种抗糖尿病药对认知障碍的潜在治疗作用，其中最近对二肽基肽酶-4（DPP-4）抑制剂进行了研究。迄今为止，DPP-4抑制剂已在动物模型中证明了神经保护作用和认知功能的改善，并在有或无认知障碍的糖尿病患者中表现出认知益处。这篇综述旨在总结潜在的机制，优势和局限性，